Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD

4상 완료 NCT04655170

대상 질환	COPD Exacerbation
임상 단계	4상
스폰서	University of Tennessee Graduate School of Medicine
상태	완료
참여자 수	60 명
중재(약물)	Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
시작일	2020년 12월 9일
완료일	2023년 1월 19일
결과 공개일	2026년 8월 3일

요약

The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized Albuterol and Ipratropium.

Difference in Modified Borg Dyspnea Scale Scores Between Groups

From enrollment to the end of treatment at Day 7 · scores on a scale

Experimental: Group 1: Revefenacin (YUPELRI) & Formoterol (Perforomist)	1.89 scores on a scale
Active Comparator: Group 2: Ipratropium Bromide (Atrovent) & Albuterol(Ventolin) as Standard of Care	1.92 scores on a scale

p-value	0.95

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster — Chiesi Farmaceutici S.p.A.
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®T — Chiesi Farmaceutici S.p.A.
Tiotropium/Salmeterol Inhalation Powder in COPD — Boehringer Ingelheim
Risk Factors, Costs, and Impacts of ED Boarding — University of Maryland, Baltimore
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructiv — United Therapeutics
Anti-Platelets in Chronic Obstructive Pulmonary Disease — Brigham and Women's Hospital

전체 임상

이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.

English 한국어 日本語中文 Русский